Linagliptin vs Sitagliptin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
Linagliptin · Tradjenta
Marketed by Boehringer Ingelheim and partners
NCT00602472 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial with 1,058 participants, and its primary endpoint was met: adjusted HbA1c change was −0.72% with linagliptin versus −0.10% with placebo (p<0.0001). The evidence is considered moderate because HbA1c is a surrogate measure rather than a hard clinical endpoint.
Reported efficacy
The First 3-point Major Adverse Cardiovascular Events (3P-MACE) (From randomization until individual day of trial completion, up to 432 weeks): The First 3-point Major Adverse Cardiovascular Events (3P-MACE) (From randomization until individual day of trial completion, up to 432 weeks): Linagliptin 20.7 Events/ 1000 patients-years vs Glimepiride 21.2 Events/ 1000 patients-years (met)
Result source: NCT01243424
Sitagliptin · Januvia
Marketed by Merck & Co. and partners
NCT00087516 · Phase 3 · completed
The trial randomized 741 participants to double-blind sitagliptin or placebo groups, providing a substantial controlled comparison. The primary endpoint, change in A1C at week 24, was statistically favorable for both sitagliptin doses (p<0.001), but A1C is a surrogate endpoint, so the evidence is rated moderate rather than strong.
Next expected readout: September 2029 · NCT07108985 (registry estimate)
Reported efficacy
Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 (Baseline and week 24): Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 (Baseline and week 24): Sitagliptin 100 mg -0.85 Percent (95% CI -0.98 to -0.72) vs Placebo -0.15 Percent (95% CI -0.28 to -0.03) (met)
Result source: NCT00086502
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Linagliptin | Sitagliptin |
|---|---|---|
| HbA1c, change | -0.6% vs 0.1%−0.6 vs placeboNCT00954447129 other results
| -0.6% vs 0.2%−0.8 vs placeboNCT000875167 other results
|
| Body weight, change (kg) | 1.4 vs -0.0+1.5 vs placeboNCT034295434 other results
| -0.5 vs -1.4vs Oral SemaglutideNCT040178321 other result
|
| HbA1c below 7% | 26.9% vs 24.5%+2.4 vs placeboNCT034295437 other results
| 49.5% vs 36.8%+12.7 vs placeboNCT014856144 other results
|
| Fasting plasma glucose, change | -0.1 vs 0.0−0.2 vs placeboNCT0095444795 other results
| -0.7 vs 0.3−0.9 vs placeboNCT000875167 other results
|
| 3-point MACE (% with event) | 20.7% vs 21.2%vs GlimepirideNCT012434242 other results
| —Not posted · NCT01529541 |
HbA1c, change
- Linagliptin
- -0.6% vs 0.1%−0.6 vs placeboNCT00954447
129 other results
- -0.7% vs -0.1% NCT00602472
- -0.5% vs 0.1% NCT00601250
- -0.6% vs -0.0% NCT01792518
- -0.7% vs -0.2% NCT01214239
- -0.7% vs -0.1% NCT01215097
- -0.8% vs -0.3% NCT00996658
- -0.8% vs -0.3% NCT01194830
- -0.6% vs 0.0% NCT01084005
- -0.5% vs -0.1% NCT01087502
- -1.1% vs -0.6% NCT00641043
- -0.4% vs 0.3% NCT00621140
- -0.9% vs -0.3% NCT02489968
- -0.6% vs 0.1% NCT01734785
- -0.9% vs -0.3% NCT02489968
- -0.7% vs 0.1% NCT01734785
- -0.6% vs -0.2% NCT02897349
- -0.4% vs -0.7% NCT01183013
- 0.3% vs -0.2% NCT03429543
- -1.3% vs -1.6% NCT01708902
- -1.3% vs -1.7% NCT01708902
- -0.8% vs -0.7% NCT01183013
- -1.1% vs -0.7% NCT01183013
- -1.3% vs -0.7% NCT01183013
- -2.1% vs -1.6% NCT01708902
- -2.3% vs -1.6% NCT01708902
- -2.2% vs -1.7% NCT01708902
- -2.4% vs -1.7% NCT01708902
- -0.5% vs 0.1% NCT00954447
- -0.5% vs 0.1% NCT00954447
- -0.6% vs 0.0% NCT00954447
- -0.6% vs 0.0% NCT00954447
- -0.6% vs 0.0% NCT00954447
- -0.5% vs 0% NCT00954447
- -0.8% vs -0.1% NCT00602472
- -0.7% vs -0.2% NCT01214239
- -0.7% vs -0.2% NCT01215097
- -0.7% vs -0.2% NCT01214239
- -0.6% vs -0.1% NCT01215097
- -0.9% vs -0.4% NCT00996658
- -0.8% vs -0.3% NCT01194830
- -0.6% vs 0.0% NCT01084005
- -0.6% vs -0.1% NCT01214239
- -0.7% vs -0.1% NCT01215097
- -0.8% vs -0.3% NCT00996658
- -0.7% vs -0.2% NCT01194830
- -0.6% vs -0.0% NCT01084005
- -0.5% vs -0.1% NCT01214239
- -0.5% vs -0.0% NCT01215097
- -0.6% vs -0.2% NCT00996658
- -0.5% vs 0.1% NCT00601250
- -0.4% vs -0.1% NCT01084005
- -1.1% vs -0.6% NCT00641043
- -0.5% vs 0.2% NCT00621140
- -0.8% vs -0.1% NCT00602472
- -0.5% vs 0.1% NCT00601250
- -0.8% vs -0.3% NCT00641043
- -0.5% vs 0.2% NCT00621140
- -0.7% vs -0.2% NCT00602472
- -0.4% vs 0.1% NCT00601250
- -0.4% vs -0.0% NCT00641043
- -0.4% vs 0.1% NCT00621140
- -0.6% vs -0.2% NCT01194830
- -0.5% vs 0.1% NCT03429543
- 0.1% vs 0.1% NCT01243424
- -0.4% vs -0.3% NCT01087502
- -0.4% vs -0.2% NCT01087502
- -0.4% vs -0.2% NCT01087502
- -0.5% vs -0.4% NCT01087502
- -0.4% vs -0.7% NCT01183013
- -0.5% vs -0.5% NCT01087502
- -0.4% vs -0.7% NCT01183013
- -0.5% vs -0.5% NCT01087502
- -0.5% vs -0.5% NCT01087502
- -0.4% vs -0.6% NCT01183013
- -0.5% vs -0.3% NCT01087502
- -0.4% vs -0.4% NCT01183013
- -0.5% vs -0.1% NCT01087502
- -0.5% vs -0.1% NCT01087502
- -0.2% vs -0.2% NCT01183013
- -0.3% vs -0.1% NCT01087502
- -0.9% vs -0.7% NCT01183013
- -1.1% vs -0.7% NCT01183013
- -1.3% vs -0.7% NCT01183013
- -0.8% vs -0.7% NCT01183013
- -1.1% vs -0.7% NCT01183013
- -1.2% vs -0.7% NCT01183013
- -0.8% vs -0.6% NCT01183013
- -1.1% vs -0.6% NCT01183013
- -1.2% vs -0.6% NCT01183013
- -0.7% vs -0.4% NCT01183013
- -0.9% vs -0.4% NCT01183013
- -1.0% vs -0.4% NCT01183013
- -0.4% vs -0.2% NCT01183013
- -0.5% vs -0.2% NCT01183013
- -0.6% vs -0.2% NCT01183013
- -0.3% vs -0.1% NCT00915772
- -0.2% vs -0.1% NCT00915772
- -1.4% vs -1.2% NCT00915772
- -1.7% vs -1.2% NCT00915772
- -0.3% vs -0.1% NCT00915772
- -0.3% vs -0.1% NCT00915772
- -1.3% vs -1.2% NCT00915772
- -1.6% vs -1.2% NCT00915772
- -1.4% vs -1.3% NCT00915772
- -1.6% vs -1.3% NCT00915772
- -0.4% vs -0.1% NCT00915772
- -0.4% vs -0.1% NCT00915772
- -1.3% vs -1.2% NCT00915772
- -1.7% vs -1.2% NCT00915772
- -1.3% vs -1.3% NCT00915772
- -1.6% vs -1.3% NCT00915772
- -0.3% vs -0.1% NCT00915772
- -0.3% vs -0.1% NCT00915772
- -0.2% vs -0.1% NCT00915772
- -0.3% vs -0.1% NCT00915772
- -1.0% vs -0.4% NCT02240680
- -0.5% vs 0.3% NCT01012037
- -0.5% vs 0.3% NCT01012037
- -1.0% vs -1.0% NCT01438814
- -0.6% vs 0.3% NCT01012037
- -0.3% vs 0.3% NCT01012037
- -0.5% vs 0.3% NCT01012037
- -0.3% vs 0.3% NCT01012037
- -0.8% vs -0.8% NCT01438814
- -0.3% vs -0.3% NCT01438814
- 7.6% vs 8% NCT02004366
- 6.6% vs 8% NCT02004366
- 7% vs 8% NCT02004366
- 8.6% vs 8% NCT02004366
- Sitagliptin
- -0.6% vs 0.2%−0.8 vs placeboNCT00087516
7 other results
- -0.8% vs -0.1% NCT00086502
- -0.8% vs 0.2% NCT00087516
- -0.0% vs 0.2% NCT01485614
- -1.1% vs -0.7% NCT02791490
- -0.1% vs -1.0% NCT01485614
- -0.2% vs -0.7% NCT01485614
- -0.5% vs -1.1% NCT01907854
Body weight, change (kg)
- Linagliptin
- 1.4 vs -0.0+1.5 vs placeboNCT03429543
4 other results
- -2.5 vs -0.3 NCT01734785
- -3.1 vs -0.3 NCT01734785
- 2.7 vs -0.0 NCT03429543
- -0.4 vs -1.1 NCT01438814
- Sitagliptin
- -0.5 vs -1.4vs Oral SemaglutideNCT04017832
1 other result
- -1.8 vs -3.3 NCT01907854
HbA1c below 7%
- Linagliptin
- 26.9% vs 24.5%+2.4 vs placeboNCT03429543
7 other results
- 13.9% vs 8.2% NCT02897349
- 16.7% vs 24.5% NCT03429543
- 43.6% vs 50% NCT01708902
- 72.1% vs 50% NCT01708902
- 77.1% vs 50% NCT01708902
- 33% vs 10% NCT01012037
- 34% vs 10% NCT01012037
- Sitagliptin
- 49.5% vs 36.8%+12.7 vs placeboNCT01485614
4 other results
- 28.8% vs 16.6% NCT02791490
- 15.6% vs 5.7% NCT02791490
- 28.4% vs 33.3% NCT01485614
- 49.5% vs 77.8% NCT01485614
Fasting plasma glucose, change
- Linagliptin
- -0.1 vs 0.0−0.2 vs placeboNCT00954447
95 other results
- -0.4 vs -0.2 NCT00954447
- -0.3 vs -0.1 NCT00954447
- -0.4 vs 0.3 NCT00954447
- -0.3 vs 0.2 NCT00954447
- -0.3 vs 0.5 NCT00602472
- -0.5 vs 0.1 NCT01214239
- -0.6 vs -0.1 NCT01215097
- -0.4 vs 0 NCT00954447
- -0.2 vs 0.1 NCT00954447
- -0.6 vs 0.0 NCT00996658
- -0.6 vs 0.6 NCT00601250
- -0.3 vs 0.4 NCT00602472
- -0.6 vs 0.6 NCT00601250
- -0.5 vs 0.3 NCT00602472
- -0.7 vs 0.2 NCT00601250
- -0.6 vs 0.3 NCT00602472
- -0.7 vs 0.3 NCT00601250
- -1.3 vs -0.6 NCT01194830
- -0.6 vs 0.6 NCT01084005
- -0.6 vs -0.1 NCT01214239
- -0.7 vs -0.1 NCT01215097
- -0.5 vs -0.1 NCT00996658
- -0.7 vs 0.5 NCT01084005
- -0.6 vs -0.1 NCT01214239
- -0.8 vs -0.3 NCT01215097
- -0.4 vs -0.0 NCT00954447
- -0.4 vs 0.2 NCT00996658
- -0.8 vs 0.4 NCT01084005
- -0.7 vs -0.0 NCT01214239
- -0.9 vs 0.3 NCT01215097
- -0.2 vs 0.7 NCT00996658
- -0.8 vs 0.3 NCT01084005
- -1.8 vs 0.3 NCT01734785
- -1.5 vs 0.3 NCT01734785
- -1.8 vs -1.0 NCT00641043
- -0.5 vs 0.8 NCT00621140
- -1.8 vs -1.1 NCT00641043
- -0.4 vs 0.7 NCT00621140
- -1.9 vs -1.1 NCT00641043
- -0.6 vs 0.6 NCT00621140
- -1.9 vs -0.9 NCT00641043
- -0.6 vs 0.4 NCT00621140
- 0.2 vs -0.2 NCT01087502
- -0.1 vs -0.1 NCT01087502
- -0.1 vs -0.0 NCT01087502
- -0.1 vs -0.6 NCT01087502
- -0.1 vs -1.6 NCT01183013
- 0 vs -1.4 NCT01183013
- -0.5 vs -0.5 NCT01087502
- -0.8 vs -1.7 NCT01708902
- -0.3 vs -1.2 NCT01183013
- -0.7 vs -0.5 NCT01087502
- -0.3 vs -0.5 NCT01087502
- -0.4 vs -1.1 NCT01183013
- -0.4 vs -1.2 NCT01183013
- 0.0 vs 0.5 NCT01087502
- -0.3 vs 0.3 NCT01087502
- -0.6 vs 0.5 NCT01087502
- -0.2 vs -0.9 NCT01183013
- -0.6 vs 0.5 NCT01087502
- -1.1 vs -1.6 NCT01183013
- -1.5 vs -1.6 NCT01183013
- -1.9 vs -1.6 NCT01183013
- -1 vs -1.4 NCT01183013
- -1.5 vs -1.4 NCT01183013
- -1.9 vs -1.4 NCT01183013
- -0.9 vs -1.2 NCT01183013
- -1.8 vs -1.2 NCT01183013
- -1.8 vs -1.2 NCT01183013
- -1.1 vs -1.1 NCT01183013
- -1.7 vs -1.1 NCT01183013
- -1.7 vs -1.1 NCT01183013
- -1 vs -1.2 NCT01183013
- -1.7 vs -1.2 NCT01183013
- -1.6 vs -1.2 NCT01183013
- -1.1 vs -0.9 NCT01183013
- -1.5 vs -0.9 NCT01183013
- -1.6 vs -0.9 NCT01183013
- -0.4 vs -0.3 NCT00915772
- -0.6 vs -0.3 NCT00915772
- -0.5 vs -0.4 NCT00915772
- -0.7 vs -0.4 NCT00915772
- -0.8 vs -0.4 NCT00915772
- -0.8 vs -0.4 NCT00915772
- -2.2 vs -1.7 NCT01708902
- -2.6 vs -1.7 NCT01708902
- -0.7 vs -0.1 NCT00915772
- -0.7 vs -0.1 NCT00915772
- -0.7 vs -0.2 NCT00915772
- -0.8 vs -0.2 NCT00915772
- -0.7 vs -0.2 NCT00915772
- -0.6 vs -0.2 NCT00915772
- -1.2 vs -0.2 NCT01012037
- -0.9 vs -0.2 NCT01012037
- -1.4 vs -1.5 NCT01438814
- Sitagliptin
- -0.7 vs 0.3−0.9 vs placeboNCT00087516
7 other results
- -0.9 vs 0.1 NCT00086502
- -0.9 vs 0.3 NCT00087516
- 0.4 vs 0.3 NCT01485614
- -1.6 vs -0.9 NCT02791490
- -0.5 vs -1.0 NCT04017832
- -0.2 vs -1.7 NCT01485614
- 0.6 vs -1.1 NCT01485614
3-point MACE (% with event)
- Linagliptin
- 20.7% vs 21.2%vs GlimepirideNCT01243424
2 other results
- 11.8% vs 12% NCT01243424
- 12.4% vs 12.1% NCT01897532
- Sitagliptin
- —Not posted · NCT01529541
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
9 other shared endpoints and safety
Coverage. Linagliptin: 13 of 13 rows · Sitagliptin: 13 of 13 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Linagliptin Rows use multiple source trials | Sitagliptin Rows use multiple source trials |
|---|---|---|
| Fasting Plasma Glucose absolute change · mmol/L No placebo or comparator arm | -1.68 mmol/L @ 24wk*5 mga,b NCT01512979 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -30.2 mg/dL as posted show 3 more doses-1.67 mmol/L @ 24wk*5 mg NCT01512979 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -30.1 mg/dL as posted -2.61 mmol/L @ 24wk*5 mg + Metformin NCT01512979 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from -47.1 mg/dL as posted -2.61 mmol/L @ 24wk*5 mg + Metformin NCT01512979 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from -47.1 mg/dL as posted | -1.9 mmol/L @ 24wka,b NCT01519674 · Phase 4 · registry result, not featured evidence · combination show 2 more doses-2.03 mmol/L @ 24wk NCT01519674 · Phase 4 · registry result, not featured evidence · combination -1.96 mmol/L @ 24wk NCT01519674 · Phase 4 · registry result, not featured evidence · combination |
| Fasting Plasma Glucose mg/dL absolute value · mmol/L | 6.1 vs 7.2 placebo mmol/L @ 12wk*b,c NCT02467478 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 109.93 mg/dL as posted 4 other source trials8.88 vs 9.27 Basal Bolus mmol/L* NCT02004366 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 160 mg/dL as posted 6.94 vs 9.27 Basal Bolus mmol/L* NCT02004366 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 125 mg/dL as posted 7.38 vs 9.27 Basal Bolus mmol/L* NCT02004366 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from 133 mg/dL as posted 7.83 vs 9.27 Basal Bolus mmol/L* NCT02004366 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from 141 mg/dL as posted | 8.33 vs 8.88 placebo mmol/L @ 6wk*a,b,c NCT00820573 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 150 mg/dL as posted show 1 more dose6.66 vs 8.88 placebo mmol/L @ 6wk* NCT00820573 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from 120 mg/dL as posted |
| Glycemic Rescue responder rate · % of participants | 7.1% (n=141) vs 2.1% (n=144) Metformin @ 24wk5 mg QDa,b,d NCT01708902 · Phase 3 · registry result, not featured evidence show 2 more doses2.1% (n=141) vs 2.1% (n=144) Metformin @ 24wk2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 1.4% (n=142) vs 2.1% (n=144) Metformin @ 24wk2.5 mg / 500 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination | 35.8% (n=95) vs 11.1% (n=9) Metformin @ 54wkb,d NCT01485614 · Phase 3 · registry result, not featured evidence |
| HbA1c absolute change · percentage points No placebo or comparator arm | -2.02% (n=113) @ 24wk5 mga,b NCT01512979 · Phase 4 · registry result, not featured evidence show 3 more doses-2.01% (n=113) @ 24wk5 mg NCT01512979 · Phase 4 · registry result, not featured evidence -2.81% (n=132) @ 24wk5 mg + Metformin NCT01512979 · Phase 4 · registry result, not featured evidence · combination -2.81% (n=132) @ 24wk5 mg + Metformin NCT01512979 · Phase 4 · registry result, not featured evidence · combination | -1.27% (n=183) @ 24wka,b NCT01519674 · Phase 4 · registry result, not featured evidence · combination show 2 more doses-1.51% (n=189) @ 24wk NCT01519674 · Phase 4 · registry result, not featured evidence · combination -1.15% (n=187) @ 24wk NCT01519674 · Phase 4 · registry result, not featured evidence · combination |
| HbA1c Less Than 6 5 responder rate · % of participants | 15.4% (n=52) vs 9.4% (n=53) placebo @ 26wk5 mga,b,e,f NCT03429543 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 1 more dose16.7% (n=6) vs 9.4% (n=53) placebo @ 26wk5 mg NCT03429543 · Phase 3 · combination · Type 2 Diabetes · phase 3 | 20% (n=95) vs 22.2% (n=9) Metformin @ 54wkb,e,f NCT01485614 · Phase 3 · registry result, not featured evidence |
| HbA1c Less Than 7 absolute value · percentage points | 22.1% (n=108) vs 11.8% (n=110) Glimepiride @ 52wk5 mgg,h,b,e,i NCT01087502 · Phase 3 · registry result, not featured evidence | 26.9% (n=182) vs 50.6% (n=176) Liraglutide @ 26wkg,h,b,e,i Yes NCT01907854 · Phase 4 · registry result, not featured evidence |
| HbA1c Less Than 7% event count · % of participants | 39.2% (n=171) vs 30% (n=170) metformin @ 54wk*linagliptin 2.5 mg bid + metformin 1000 mg bida,b,e,j NCT00915772 · Phase 3 · registry result, not featured evidence · combination · converted to % from 67 participant as posted show 1 more dose25.3% (n=225) vs 30% (n=170) metformin @ 54wk*linagliptin 2.5 mg bid + metformin 500 mg bid NCT00915772 · Phase 3 · registry result, not featured evidence · combination · converted to % from 57 participant as posted | 36.5% (n=334) vs 43.3% (n=321) Oral Semaglutide @ 26wk*100 mgb,e,j Yes NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 122 Participants as posted |
| HbA1c Less Than 7% responder rate · % of participants No placebo or comparator arm | 27.1% (n=70) @ 12wk5 mg QDa,h,b,k NCT01708902 · Phase 3 · registry result, not featured evidence show 1 more dose58.8% (n=68) @ 12wk2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination | 26.6% (n=94) @ 20wka,h,b,k NCT00870194 · Phase 4 · registry result, not featured evidence show 1 more dose41.7% (n=108) @ 20wk NCT00870194 · Phase 4 · registry result, not featured evidence · combination |
| PPG 2h Change mg/dL absolute change · mmol/L | -2.86 vs -1.7 pioglitazone mmol/L @ 30wk*5 mga,h,b,l NCT01183013 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -51.61 mg/dL as posted show 3 more doses-3.73 vs -1.7 pioglitazone mmol/L @ 30wk*5 mg + 15 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -67.26 mg/dL as posted -4.88 vs -1.7 pioglitazone mmol/L @ 30wk*5 mg + 30 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -87.94 mg/dL as posted -4.71 vs -1.7 pioglitazone mmol/L @ 30wk*5 mg + 45 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -84.77 mg/dL as posted | -6.01 vs -2.47 Sitagliptin mmol/L @ 8wk*h,b,l NCT00729326 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -108.35 mg/dL as posted |
| Dropout rate | 7.3%m NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 57 more results7.5% NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —5 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 4.3% NCT01243424 · Phase 3 0% NCT02467478 · Phase 4 · registry result, not featured evidence 15%5 mg per day NCT02372630 · Phase 4 · registry result, not featured evidence 24% NCT01897532 · Phase 4 · registry result, not featured evidence 5.3%5 mg NCT02240680 · Phase 4 · registry result, not featured evidence —5 mg NCT02240680 · Phase 4 · registry result, not featured evidence —5 mg NCT02240680 · Phase 4 · registry result, not featured evidence 0%Linagliptin In-hospital NCT02004366 · Phase 4 · registry result, not featured evidence —Linagliptin on Discharge NCT02004366 · Phase 4 · registry result, not featured evidence —Linagliptin+50%Glargine Dose on d/ NCT02004366 · Phase 4 · registry result, not featured evidence · combination —Linagliptin+80%Glargine Dose on d/ NCT02004366 · Phase 4 · registry result, not featured evidence · combination 20% NCT02350478 · Phase 4 · registry result, not featured evidence 0% NCT01969084 · Phase 4 · registry result, not featured evidence 14%5 mg NCT01512979 · Phase 4 · registry result, not featured evidence 11.9%5 mg + Metformin NCT01512979 · Phase 4 · registry result, not featured evidence · combination 4.1%5 mg once daily + metformin once daily NCT01438814 · Phase 4 · registry result, not featured evidence · combination 5.8% NCT02897349 · Phase 3 · registry result, not featured evidence —25 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination —10 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination 3.8%5 mg NCT01792518 · Phase 3 · registry result, not featured evidence —25 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination —10 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination —5 mg NCT01708902 · Phase 3 · registry result, not featured evidence 9.9%5 mg QD NCT01708902 · Phase 3 · registry result, not featured evidence —5 mg QD NCT01708902 · Phase 3 · registry result, not featured evidence 11.6%5 mg QD NCT01708902 · Phase 3 · registry result, not featured evidence —5 mg QD, then 2.5 mg / Metformin after week 12 NCT01708902 · Phase 3 · registry result, not featured evidence · combination —2.5 mg / 1000 mg NCT01708902 · Phase 3 · registry result, not featured evidence · combination 9.7%2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination —2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 10.9%2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 6.8%2.5 mg / 500 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 22.2%5 mg NCT01183013 · Phase 3 · registry result, not featured evidence 28.6%5 mg + 15 mg / 5 mg + 30 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 33.8%5 mg + 30 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 27.8%5 mg + 45 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 6.8%5 mg NCT01087502 · Phase 3 · registry result, not featured evidence 9%5 mg NCT01214239 · Phase 3 · registry result, not featured evidence 6.8%5 mg once daily NCT01215097 · Phase 3 · registry result, not featured evidence 11.3%5 mg tablet NCT00996658 · Phase 3 · registry result, not featured evidence 2.4%A-GI+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 3.7%Bigu+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 12.1%Glin+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 6.8%Glit+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 7.7%SU+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 24.5%5 mg NCT01194830 · Phase 3 · registry result, not featured evidence 13.9%5 mg NCT00954447 · Phase 3 · registry result, not featured evidence 17%linagliptin 2.5 mg bid + metformin 1000 mg bid NCT00915772 · Phase 3 · registry result, not featured evidence · combination 20.4%linagliptin 2.5 mg bid + metformin 500 mg bid NCT00915772 · Phase 3 · registry result, not featured evidence · combination 9.9%5 mg NCT01084005 · Phase 3 · registry result, not featured evidence 21.2% NCT00740051 · Phase 3 · registry result, not featured evidence 5.8% NCT00641043 · Phase 3 · registry result, not featured evidence · combination 5.4% NCT00621140 · Phase 3 · registry result, not featured evidence 4.5%5 mg once daily NCT01012037 · Phase 2 · registry result, not featured evidence 7.2%2.5 mg twice daily NCT01012037 · Phase 2 · registry result, not featured evidence | 74.6%100 mgn NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 37 more results67.6%100 mg/100 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 69.1%200 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 67.6%200 mg/200 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 14.9%100 mg NCT00086502 · Phase 3 · combination · Type 2 Diabetes · phase 3 9% NCT02556918 · Phase 4 · registry result, not featured evidence —100 mg NCT03267576 · Phase 4 · registry result, not featured evidence 0% NCT02920918 · Phase 4 · registry result, not featured evidence —Sitagliptin (Diabetics and Control NCT02639637 · Phase 4 · registry result, not featured evidence —Sitagliptin and Valsartan (Control NCT02639637 · Phase 4 · registry result, not featured evidence · combination — NCT02256189 · Phase 4 · registry result, not featured evidence — NCT01859793 · Phase 4 · registry result, not featured evidence 0% NCT02312063 · Phase 4 · registry result, not featured evidence —Metformin and Sitagliptin NCT01845831 · Phase 4 · registry result, not featured evidence · combination —Metformin and Sitagliptin + Glargi NCT01845831 · Phase 4 · registry result, not featured evidence · combination —Metformin and Sitagliptin + Glargi NCT01845831 · Phase 4 · registry result, not featured evidence · combination 0.7%Sitagliptin + Glargine (Hospital) NCT01845831 · Phase 4 · registry result, not featured evidence · combination 0%50 mg NCT02318693 · Phase 4 · registry result, not featured evidence 6.4% NCT01907854 · Phase 4 · registry result, not featured evidence — NCT01686932 · Phase 4 · registry result, not featured evidence 10.8%BID + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination 6.7%BID + Sita + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination 6.2%OD + Sita + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination —Metformin Plus Sitagliptin NCT00820573 · Phase 4 · registry result, not featured evidence · combination —Sitagliptin NCT00820573 · Phase 4 · registry result, not featured evidence 12.9%Sitagliptin + SSI Prn NCT01378117 · Phase 4 · registry result, not featured evidence · combination —Sitagliptin and Glargine + SSI NCT01378117 · Phase 4 · registry result, not featured evidence · combination 3% NCT01131182 · Phase 4 · registry result, not featured evidence 20.5%Exenatide + Placebo NCT00870194 · Phase 4 · registry result, not featured evidence 10.9%Exenatide + Sitagliptin NCT00870194 · Phase 4 · registry result, not featured evidence · combination 5.6% NCT00686634 · Phase 4 · registry result, not featured evidence — NCT00729326 · Phase 4 · registry result, not featured evidence 2.5%100 mg NCT04017832 · Phase 3 · registry result, not featured evidence 1% NCT01485614 · Phase 3 · registry result, not featured evidence 4.8%Sitagliptin/Metformin NCT01760447 · Phase 3 · registry result, not featured evidence 10.6%Sitagliptin/Metformin XR NCT01760447 · Phase 3 · registry result, not featured evidence 2.6% NCT03115112 · Phase 3 · registry result, not featured evidence 1.3% NCT02791490 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | 2.9%m NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 57 more results1.7% NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —5 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 — NCT01243424 · Phase 3 — NCT02467478 · Phase 4 · registry result, not featured evidence —5 mg per day NCT02372630 · Phase 4 · registry result, not featured evidence 10.3% NCT01897532 · Phase 4 · registry result, not featured evidence 4%5 mg NCT02240680 · Phase 4 · registry result, not featured evidence —5 mg NCT02240680 · Phase 4 · registry result, not featured evidence —5 mg NCT02240680 · Phase 4 · registry result, not featured evidence —Linagliptin In-hospital NCT02004366 · Phase 4 · registry result, not featured evidence —Linagliptin on Discharge NCT02004366 · Phase 4 · registry result, not featured evidence —Linagliptin+50%Glargine Dose on d/ NCT02004366 · Phase 4 · registry result, not featured evidence · combination —Linagliptin+80%Glargine Dose on d/ NCT02004366 · Phase 4 · registry result, not featured evidence · combination — NCT02350478 · Phase 4 · registry result, not featured evidence 0% NCT01969084 · Phase 4 · registry result, not featured evidence 1.3%5 mg NCT01512979 · Phase 4 · registry result, not featured evidence 1.3%5 mg + Metformin NCT01512979 · Phase 4 · registry result, not featured evidence · combination 0.9%5 mg once daily + metformin once daily NCT01438814 · Phase 4 · registry result, not featured evidence · combination 2.9% NCT02897349 · Phase 3 · registry result, not featured evidence —25 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination —10 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination 2.2%5 mg NCT01792518 · Phase 3 · registry result, not featured evidence —25 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination —10 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination —5 mg NCT01708902 · Phase 3 · registry result, not featured evidence 4.2%5 mg QD NCT01708902 · Phase 3 · registry result, not featured evidence —5 mg QD NCT01708902 · Phase 3 · registry result, not featured evidence 2%5 mg QD NCT01708902 · Phase 3 · registry result, not featured evidence —5 mg QD, then 2.5 mg / Metformin after week 12 NCT01708902 · Phase 3 · registry result, not featured evidence · combination —2.5 mg / 1000 mg NCT01708902 · Phase 3 · registry result, not featured evidence · combination 6.9%2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination —2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 4.8%2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 1.4%2.5 mg / 500 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 3.7%5 mg NCT01183013 · Phase 3 · registry result, not featured evidence 7.9%5 mg + 15 mg / 5 mg + 30 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 7.5%5 mg + 30 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 4.5%5 mg + 45 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 3.4%5 mg NCT01087502 · Phase 3 · registry result, not featured evidence 2%5 mg NCT01214239 · Phase 3 · registry result, not featured evidence 1.5%5 mg once daily NCT01215097 · Phase 3 · registry result, not featured evidence 2.7%5 mg tablet NCT00996658 · Phase 3 · registry result, not featured evidence 1.2%A-GI+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 2.4%Bigu+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 9.1%Glin+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 0%Glit+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 4.9%SU+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 1.8%5 mg NCT01194830 · Phase 3 · registry result, not featured evidence 4%5 mg NCT00954447 · Phase 3 · registry result, not featured evidence 6.4%linagliptin 2.5 mg bid + metformin 1000 mg bid NCT00915772 · Phase 3 · registry result, not featured evidence · combination 5.8%linagliptin 2.5 mg bid + metformin 500 mg bid NCT00915772 · Phase 3 · registry result, not featured evidence · combination 4.9%5 mg NCT01084005 · Phase 3 · registry result, not featured evidence 2.6% NCT00740051 · Phase 3 · registry result, not featured evidence 1.5% NCT00641043 · Phase 3 · registry result, not featured evidence · combination 1.5% NCT00621140 · Phase 3 · registry result, not featured evidence 1.3%5 mg once daily NCT01012037 · Phase 2 · registry result, not featured evidence 3.6%2.5 mg twice daily NCT01012037 · Phase 2 · registry result, not featured evidence | 2.3%100 mgn NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 37 more results4.2%100 mg/100 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 4.9%200 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 4%200 mg/200 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 6.3%100 mg NCT00086502 · Phase 3 · combination · Type 2 Diabetes · phase 3 — NCT02556918 · Phase 4 · registry result, not featured evidence —100 mg NCT03267576 · Phase 4 · registry result, not featured evidence — NCT02920918 · Phase 4 · registry result, not featured evidence —Sitagliptin (Diabetics and Control NCT02639637 · Phase 4 · registry result, not featured evidence —Sitagliptin and Valsartan (Control NCT02639637 · Phase 4 · registry result, not featured evidence · combination — NCT02256189 · Phase 4 · registry result, not featured evidence — NCT01859793 · Phase 4 · registry result, not featured evidence — NCT02312063 · Phase 4 · registry result, not featured evidence —Metformin and Sitagliptin NCT01845831 · Phase 4 · registry result, not featured evidence · combination —Metformin and Sitagliptin + Glargi NCT01845831 · Phase 4 · registry result, not featured evidence · combination —Metformin and Sitagliptin + Glargi NCT01845831 · Phase 4 · registry result, not featured evidence · combination —Sitagliptin + Glargine (Hospital) NCT01845831 · Phase 4 · registry result, not featured evidence · combination —50 mg NCT02318693 · Phase 4 · registry result, not featured evidence — NCT01907854 · Phase 4 · registry result, not featured evidence — NCT01686932 · Phase 4 · registry result, not featured evidence 1.5%BID + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination 1.5%BID + Sita + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination 0%OD + Sita + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination —Metformin Plus Sitagliptin NCT00820573 · Phase 4 · registry result, not featured evidence · combination —Sitagliptin NCT00820573 · Phase 4 · registry result, not featured evidence —Sitagliptin + SSI Prn NCT01378117 · Phase 4 · registry result, not featured evidence · combination —Sitagliptin and Glargine + SSI NCT01378117 · Phase 4 · registry result, not featured evidence · combination — NCT01131182 · Phase 4 · registry result, not featured evidence 7.9%Exenatide + Placebo NCT00870194 · Phase 4 · registry result, not featured evidence 3.9%Exenatide + Sitagliptin NCT00870194 · Phase 4 · registry result, not featured evidence · combination — NCT00686634 · Phase 4 · registry result, not featured evidence — NCT00729326 · Phase 4 · registry result, not featured evidence —100 mg NCT04017832 · Phase 3 · registry result, not featured evidence — NCT01485614 · Phase 3 · registry result, not featured evidence —Sitagliptin/Metformin NCT01760447 · Phase 3 · registry result, not featured evidence —Sitagliptin/Metformin XR NCT01760447 · Phase 3 · registry result, not featured evidence 0.5% NCT03115112 · Phase 3 · registry result, not featured evidence — NCT02791490 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 3.2%m NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 57 more results3.4% NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 10.4%5 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 46.4% NCT01243424 · Phase 3 7.1% NCT02467478 · Phase 4 · registry result, not featured evidence 0%5 mg per day NCT02372630 · Phase 4 · registry result, not featured evidence 37% NCT01897532 · Phase 4 · registry result, not featured evidence —5 mg NCT02240680 · Phase 4 · registry result, not featured evidence 12.6%5 mg NCT02240680 · Phase 4 · registry result, not featured evidence 25%5 mg NCT02240680 · Phase 4 · registry result, not featured evidence 0.8%Linagliptin In-hospital NCT02004366 · Phase 4 · registry result, not featured evidence 13%Linagliptin on Discharge NCT02004366 · Phase 4 · registry result, not featured evidence 15.1%Linagliptin+50%Glargine Dose on d/ NCT02004366 · Phase 4 · registry result, not featured evidence · combination 23.1%Linagliptin+80%Glargine Dose on d/ NCT02004366 · Phase 4 · registry result, not featured evidence · combination 15% NCT02350478 · Phase 4 · registry result, not featured evidence 5.3% NCT01969084 · Phase 4 · registry result, not featured evidence 1.3%5 mg NCT01512979 · Phase 4 · registry result, not featured evidence 1.9%5 mg + Metformin NCT01512979 · Phase 4 · registry result, not featured evidence · combination 0.6%5 mg once daily + metformin once daily NCT01438814 · Phase 4 · registry result, not featured evidence · combination 9.6% NCT02897349 · Phase 3 · registry result, not featured evidence 5.2%25 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination 0.9%10 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination 9.3%5 mg NCT01792518 · Phase 3 · registry result, not featured evidence 3.6%25 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination 4.5%10 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination 0%5 mg NCT01708902 · Phase 3 · registry result, not featured evidence —5 mg QD NCT01708902 · Phase 3 · registry result, not featured evidence 1.4%5 mg QD NCT01708902 · Phase 3 · registry result, not featured evidence 1.4%5 mg QD NCT01708902 · Phase 3 · registry result, not featured evidence 3.2%5 mg QD, then 2.5 mg / Metformin after week 12 NCT01708902 · Phase 3 · registry result, not featured evidence · combination 1.5%2.5 mg / 1000 mg NCT01708902 · Phase 3 · registry result, not featured evidence · combination —2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 1.4%2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 2.7%2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 0.7%2.5 mg / 500 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 6.7%5 mg NCT01183013 · Phase 3 · registry result, not featured evidence 7.1%5 mg + 15 mg / 5 mg + 30 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 11.3%5 mg + 30 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 7.5%5 mg + 45 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 24.8%5 mg NCT01087502 · Phase 3 · registry result, not featured evidence 0.5%5 mg NCT01214239 · Phase 3 · registry result, not featured evidence 2%5 mg once daily NCT01215097 · Phase 3 · registry result, not featured evidence 2.2%5 mg tablet NCT00996658 · Phase 3 · registry result, not featured evidence 8.2%A-GI+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 9.8%Bigu+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 7.6%Glin+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 2.7%Glit+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 4.9%SU+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 0.9%5 mg NCT01194830 · Phase 3 · registry result, not featured evidence 13.8%5 mg NCT00954447 · Phase 3 · registry result, not featured evidence 8.2%linagliptin 2.5 mg bid + metformin 1000 mg bid NCT00915772 · Phase 3 · registry result, not featured evidence · combination 5.3%linagliptin 2.5 mg bid + metformin 500 mg bid NCT00915772 · Phase 3 · registry result, not featured evidence · combination 8.6%5 mg NCT01084005 · Phase 3 · registry result, not featured evidence 0.7% NCT00740051 · Phase 3 · registry result, not featured evidence 3.1% NCT00641043 · Phase 3 · registry result, not featured evidence · combination 3% NCT00621140 · Phase 3 · registry result, not featured evidence 2.2%5 mg once daily NCT01012037 · Phase 2 · registry result, not featured evidence 4%2.5 mg twice daily NCT01012037 · Phase 2 · registry result, not featured evidence | 7.7%100 mgn NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 37 more results10.1%100 mg/100 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 10.6%200 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 10%200 mg/200 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.9%100 mg NCT00086502 · Phase 3 · combination · Type 2 Diabetes · phase 3 80% NCT02556918 · Phase 4 · registry result, not featured evidence 0%100 mg NCT03267576 · Phase 4 · registry result, not featured evidence 5.3% NCT02920918 · Phase 4 · registry result, not featured evidence 0%Sitagliptin (Diabetics and Control NCT02639637 · Phase 4 · registry result, not featured evidence 0%Sitagliptin and Valsartan (Control NCT02639637 · Phase 4 · registry result, not featured evidence · combination 0% NCT02256189 · Phase 4 · registry result, not featured evidence 0% NCT01859793 · Phase 4 · registry result, not featured evidence 0% NCT02312063 · Phase 4 · registry result, not featured evidence —Metformin and Sitagliptin NCT01845831 · Phase 4 · registry result, not featured evidence · combination —Metformin and Sitagliptin + Glargi NCT01845831 · Phase 4 · registry result, not featured evidence · combination —Metformin and Sitagliptin + Glargi NCT01845831 · Phase 4 · registry result, not featured evidence · combination 7.2%Sitagliptin + Glargine (Hospital) NCT01845831 · Phase 4 · registry result, not featured evidence · combination 0%50 mg NCT02318693 · Phase 4 · registry result, not featured evidence 3.4% NCT01907854 · Phase 4 · registry result, not featured evidence 2% NCT01686932 · Phase 4 · registry result, not featured evidence 3.6%BID + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination 2.6%BID + Sita + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination 2.1%OD + Sita + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination 0%Metformin Plus Sitagliptin NCT00820573 · Phase 4 · registry result, not featured evidence · combination 0%Sitagliptin NCT00820573 · Phase 4 · registry result, not featured evidence 3.7%Sitagliptin + SSI Prn NCT01378117 · Phase 4 · registry result, not featured evidence · combination 0%Sitagliptin and Glargine + SSI NCT01378117 · Phase 4 · registry result, not featured evidence · combination 0% NCT01131182 · Phase 4 · registry result, not featured evidence 3.1%Exenatide + Placebo NCT00870194 · Phase 4 · registry result, not featured evidence 4.7%Exenatide + Sitagliptin NCT00870194 · Phase 4 · registry result, not featured evidence · combination 0% NCT00686634 · Phase 4 · registry result, not featured evidence 2.7% NCT00729326 · Phase 4 · registry result, not featured evidence 4.2%100 mg NCT04017832 · Phase 3 · registry result, not featured evidence 10.5% NCT01485614 · Phase 3 · registry result, not featured evidence 6.5%Sitagliptin/Metformin NCT01760447 · Phase 3 · registry result, not featured evidence 6.7%Sitagliptin/Metformin XR NCT01760447 · Phase 3 · registry result, not featured evidence 2.1% NCT03115112 · Phase 3 · registry result, not featured evidence 1.3% NCT02791490 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | m hypoglycaemia 22.7% (placebo 14.8%) upper respiratory tract infection 5.8% (placebo 9.1%) hyperglycaemia 5.6% (placebo 8.7%) NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 50 more resultshyperglycaemia 5.2% (placebo 14.7%) nasopharyngitis 5.2% (placebo 5.1%) NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 5 mg hypoglycaemia 20.8% (placebo 12.1%) headache 15.6% (placebo 15.5%) blood ketone body increased 10.4% (placebo 3.4%) NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 hypoglycaemia 29.3% (placebo 28.8%) hypertension 6.2% (placebo 6.7%) hyperglycaemia 6% (placebo 6.9%) NCT01897532 · Phase 4 · registry result, not featured evidence 5 mg hypoglycaemia 33.8% (placebo 25.2%) viral upper respiratory tract infection 7.3% (placebo 5.3%) urinary tract infection 6.6% (placebo 6%) NCT02240680 · Phase 4 · registry result, not featured evidence 5 mg hypoglycaemia 38.5% (placebo 25.2%) viral upper respiratory tract infection 21.2% (placebo 5.3%) bronchitis 9.6% (placebo 2.6%) NCT02240680 · Phase 4 · registry result, not featured evidence infections 5.5% renal 4.7% surgical reintervention 4.7% NCT02004366 · Phase 4 · registry result, not featured evidence gastrointestinal 1.1% musculoskeletal 1.1% skin 1.1% NCT02004366 · Phase 4 · registry result, not featured evidence gastrointestinal 1.1% hematologic 0% infections 0% NCT02004366 · Phase 4 · registry result, not featured evidence · combination gastrointestinal 0% hematologic 0% infections 0% NCT02004366 · Phase 4 · registry result, not featured evidence · combination dorsal pain 5% (placebo 0%) nausea 5% (placebo 4.3%) toothache 5% (placebo 0%) NCT02350478 · Phase 4 · registry result, not featured evidence increased creatinine and bun, reduced gfr 5.3% (placebo 13.6%) pneumonia 5.3% (placebo 0%) cramping in the calf muscle during the graded exercise test 0% (placebo 4.5%) NCT01969084 · Phase 4 · registry result, not featured evidence 5 mg dyslipidaemia 14% hyperglycaemia 12.7% urinary tract infection 8.9% NCT01512979 · Phase 4 · registry result, not featured evidence 5 mg + Metformin dyslipidaemia 8.8% headache 6.3% urinary tract infection 6.3% NCT01512979 · Phase 4 · registry result, not featured evidence · combination 5 mg once daily + metformin once daily diarrhoea 18% abdominal pain 6.7% nausea 6.7% NCT01438814 · Phase 4 · registry result, not featured evidence · combination hypoglycaemia 17.3% (placebo 12.7%) upper respiratory tract infection 13.5% (placebo 12.7%) hyperuricaemia 5.8% (placebo 1%) NCT02897349 · Phase 3 · registry result, not featured evidence 25 mg + 5 mg viral upper respiratory tract infection 26.7% (placebo 22.2%) blood ketone body increased 13.8% (placebo 10.2%) back pain 6% (placebo 2.8%) NCT02489968 · Phase 3 · registry result, not featured evidence · combination 10 mg + 5 mg viral upper respiratory tract infection 15% (placebo 22.2%) back pain 2.8% (placebo 2.8%) contusion 2.8% (placebo 0.9%) NCT02489968 · Phase 3 · registry result, not featured evidence · combination 5 mg hypoglycaemia 13.2% (placebo 5.6%) nasopharyngitis 7.1% (placebo 5.6%) upper respiratory tract infection 2.2% (placebo 5.1%) NCT01792518 · Phase 3 · registry result, not featured evidence 25 mg + 5 mg nasopharyngitis 3.6% (placebo 7.3%) lipase increased 2.7% (placebo 5.5%) urinary tract infection 2.7% (placebo 6.4%) NCT01734785 · Phase 3 · registry result, not featured evidence · combination 10 mg + 5 mg urinary tract infection 7.1% (placebo 6.4%) nasopharyngitis 4.5% (placebo 7.3%) lipase increased 3.6% (placebo 5.5%) NCT01734785 · Phase 3 · registry result, not featured evidence · combination 5 mg diarrhoea 3% hyperuricaemia 3% dizziness 0% NCT01708902 · Phase 3 · registry result, not featured evidence 5 mg QD hyperglycaemia 16.9% hyperuricaemia 5.6% nasopharyngitis 5.6% NCT01708902 · Phase 3 · registry result, not featured evidence 5 mg QD hyperuricaemia 7.5% hyperglycaemia 4.8% upper respiratory tract infection 4.1% NCT01708902 · Phase 3 · registry result, not featured evidence 5 mg QD, then 2.5 mg / Metformin after week 12 hyperuricaemia 19.4% dizziness 6.5% hyperglycaemia 6.5% NCT01708902 · Phase 3 · registry result, not featured evidence · combination 2.5 mg / 1000 mg hyperuricaemia 6.2% hyperglycaemia 3.1% diarrhoea 1.5% NCT01708902 · Phase 3 · registry result, not featured evidence · combination 2.5 mg / 1000 mg BID diarrhoea 5.6% hyperuricaemia 5.6% upper respiratory tract infection 5.6% NCT01708902 · Phase 3 · registry result, not featured evidence · combination 2.5 mg / 1000 mg BID diarrhoea 9.5% hyperuricaemia 7.5% upper respiratory tract infection 7.5% NCT01708902 · Phase 3 · registry result, not featured evidence · combination 2.5 mg / 500 mg BID upper respiratory tract infection 8.2% hyperuricaemia 5.4% diarrhoea 4.8% NCT01708902 · Phase 3 · registry result, not featured evidence · combination 5 mg hyperglycaemia 10.4% nasopharyngitis 7.4% hypertension 6.7% NCT01183013 · Phase 3 · registry result, not featured evidence 5 mg + 15 mg / 5 mg + 30 mg diarrhoea 7.9% nasopharyngitis 7.1% back pain 6.3% NCT01183013 · Phase 3 · registry result, not featured evidence · combination 5 mg + 30 mg oedema 9% dizziness 6.8% oedema peripheral 6.8% NCT01183013 · Phase 3 · registry result, not featured evidence · combination 5 mg + 45 mg oedema peripheral 11.3% back pain 9% urinary tract infection 5.3% NCT01183013 · Phase 3 · registry result, not featured evidence · combination 5 mg hypoglycaemia 59.3% nasopharyngitis 18.6% hyperglycaemia 17.7% NCT01087502 · Phase 3 · registry result, not featured evidence 5 mg hyperlipidaemia 5.5% (placebo 3%) hyperglycaemia 2% (placebo 4%) NCT01214239 · Phase 3 · registry result, not featured evidence 5 mg once daily hyperglycaemia 4.9% (placebo 5%) hyperlipidaemia 4.4% (placebo 4%) diarrhoea 2.4% (placebo 1%) NCT01215097 · Phase 3 · registry result, not featured evidence 5 mg tablet anaemia 7.1% (placebo 6.7%) hyperglycaemia 6% (placebo 7.9%) hypoglycaemia 5.5% (placebo 4.5%) NCT00996658 · Phase 3 · registry result, not featured evidence nasopharyngitis 41.2% back pain 5.9% constipation 5.9% NCT01204294 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 36.6% bronchitis 11% arthralgia 6.1% NCT01204294 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 45.5% pharyngitis 7.6% constipation 4.5% NCT01204294 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 33.8% upper respiratory tract inflammation 8.1% arthralgia 5.4% NCT01204294 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 31.5% hypoglycaemia 14% contusion 7% NCT01204294 · Phase 3 · registry result, not featured evidence · combination 5 mg urinary tract infection 6.6% (placebo 3.3%) hyperglycaemia 2.8% (placebo 9.2%) NCT01194830 · Phase 3 · registry result, not featured evidence 5 mg hypoglycaemia 30.3% (placebo 31.3%) hyperglycaemia 14.3% (placebo 17.8%) nasopharyngitis 11.3% (placebo 9.8%) NCT00954447 · Phase 3 · registry result, not featured evidence linagliptin 2.5 mg bid + metformin 1000 mg bid diabetes mellitus 9.9% diarrhoea 7% nasopharyngitis 7% NCT00915772 · Phase 3 · registry result, not featured evidence · combination linagliptin 2.5 mg bid + metformin 500 mg bid hyperglycaemia 12.9% diabetes mellitus 8% glomerular filtration rate decreased 6.2% NCT00915772 · Phase 3 · registry result, not featured evidence · combination 5 mg hypoglycaemia 22.8% (placebo 16.5%) nasopharyngitis 10.5% (placebo 8.9%) diarrhoea 5.6% (placebo 2.5%) NCT01084005 · Phase 3 · registry result, not featured evidence hyperglycaemia 14.6% nasopharyngitis 9.9% dizziness 7.3% NCT00740051 · Phase 3 · registry result, not featured evidence nasopharyngitis 9.3% (placebo 8.5%) upper respiratory tract infection 3.5% (placebo 7.7%) NCT00641043 · Phase 3 · registry result, not featured evidence · combination hyperglycaemia 8.6% (placebo 22.8%) NCT00621140 · Phase 3 · registry result, not featured evidence | 100 mgn upper respiratory tract infection 13.1% dizziness 11.5% nasopharyngitis 9.2% NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 30 more results100 mg/100 mg upper respiratory tract infection 15.1% dizziness 10.5% nasopharyngitis 8.8% NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 200 mg upper respiratory tract infection 11.4% arthralgia 9.8% blood glucose increased 8.9% NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 200 mg/200 mg upper respiratory tract infection 16.4% dizziness 12.4% influenza 8.8% NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 100 mg any infections and infestations 6.3% (placebo 3.4%) upper respiratory tract infection 6.3% (placebo 3.4%) any nervous system disorders 5.1% (placebo 3.9%) NCT00086502 · Phase 3 · combination · Type 2 Diabetes · phase 3 infection 2% (placebo 2%) headache 1% (placebo 1%) loss of appetite 1% (placebo 0%) NCT02556918 · Phase 4 · registry result, not featured evidence 100 mg headache 1.6% hypertension 1.6% diarrhoea 0% NCT03267576 · Phase 4 · registry result, not featured evidence acute kidney injury 15.8% arrhythmic events 5.3% genital infection 5.3% NCT02920918 · Phase 4 · registry result, not featured evidence light-headedness 7.7% (placebo 7.7%) paresthesias 7.7% (placebo 0%) nausea 0% (placebo 7.7%) NCT02639637 · Phase 4 · registry result, not featured evidence light-headedness 0% (placebo 7.7%) nausea 0% (placebo 7.7%) paresthesias 0% (placebo 0%) NCT02639637 · Phase 4 · registry result, not featured evidence · combination rash 0% (placebo 2.8%) NCT01859793 · Phase 4 · registry result, not featured evidence hypoglycemia 0% NCT02312063 · Phase 4 · registry result, not featured evidence urinary tract infection 1.4% wound infection 0% NCT01845831 · Phase 4 · registry result, not featured evidence · combination 50 mg erythema 38.5% hypoglycaemia 7.7% periodontitis 7.7% NCT02318693 · Phase 4 · registry result, not featured evidence diarrhoea 9.3% nausea 7.8% upper respiratory tract infection 6.4% NCT01907854 · Phase 4 · registry result, not featured evidence hypoglycaemia 14% blood glucose decreased 6% NCT01686932 · Phase 4 · registry result, not featured evidence influenza 5.7% nasopharyngitis 4.7% diarrhoea 4.2% NCT01519674 · Phase 4 · registry result, not featured evidence · combination headache 5.7% nasopharyngitis 5.7% influenza 2.6% NCT01519674 · Phase 4 · registry result, not featured evidence · combination diarrhoea 5.3% influenza 5.3% headache 4.2% NCT01519674 · Phase 4 · registry result, not featured evidence · combination hyperglycemia 11.1% pressure ulcer/skin ulcer 11.1% hypoglycemia 3.7% NCT01378117 · Phase 4 · registry result, not featured evidence · combination hypoglycemia 6.9% pneumonia 6.9% urinary tract infection 6.9% NCT01378117 · Phase 4 · registry result, not featured evidence · combination headache 4.9% dizziness 3.9% hyperhidrosis 3.7% NCT01131182 · Phase 4 · registry result, not featured evidence nausea 15.7% vomiting 10.2% nasopharyngitis 8.7% NCT00870194 · Phase 4 · registry result, not featured evidence nausea 10.2% nasopharyngitis 7.8% headache 7% NCT00870194 · Phase 4 · registry result, not featured evidence · combination nausea 37% vomiting 20.5% headache 12.3% NCT00729326 · Phase 4 · registry result, not featured evidence 100 mg upper respiratory tract infection 7.8% diarrhoea 4.5% nausea 3.9% NCT04017832 · Phase 3 · registry result, not featured evidence hypoglycaemia 16.8% nasopharyngitis 15.8% upper respiratory tract infection 12.6% NCT01485614 · Phase 3 · registry result, not featured evidence hypoglycaemia 16.1% upper respiratory tract infection 14.5% diarrhoea 11.3% NCT01760447 · Phase 3 · registry result, not featured evidence hypoglycaemia 20% upper respiratory tract infection 11.1% abdominal pain 8.9% NCT01760447 · Phase 3 · registry result, not featured evidence nasopharyngitis 13% hypoglycemia 5.2% influenza 5.2% NCT03115112 · Phase 3 · registry result, not featured evidence diarrhoea 7.9% (placebo 4.8%) NCT02791490 · Phase 3 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cAssessment timepoints differ: 6 weeks versus 12 weeks.
- dAssessment timepoints differ: 54 weeks versus 24 weeks.
- eTreatment context has not been resolved for both arms.
- fAssessment timepoints differ: 54 weeks versus 26 weeks.
- gThe reported result categories differ.
- hTrial phases differ: Phase 4 versus Phase 3.
- iAssessment timepoints differ: 26 weeks versus 52 weeks.
- jAssessment timepoints differ: 26 weeks versus 54 weeks.
- kAssessment timepoints differ: 20 weeks versus 12 weeks.
- lAssessment timepoints differ: 8 weeks versus 30 weeks.
- mPopulation comparability has not been reviewed for 55 of these studies.
- nPopulation comparability has not been reviewed for 33 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Linagliptin
show 9 more results
show 1 more result
show 4 more results
show 1 more result
show 1 more result
show 2 more results
+ 47 further endpoints in the CSV export.
Sitagliptin
show 3 more results
show 3 more results
show 1 more result
show 2 more results
show 1 more result
show 2 more results
+ 62 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Linagliptin's landscape · Sitagliptin's landscape